Dotmatics
is pleased to announce that it has licensed its enterprise query,
reporting, registration and data management tools to The Institute of
Cancer Research (ICR). The solution will primarily be used in the
Cancer Research UK Centre for Cancer Therapeutics to query, browse,
analyze and share chemical, biological and drug metabolism information
across research programs and project teams. Dotmatics and the ICR will
work closely together to identify and develop new tools to help
progress scientific efforts, especially those applicable to research
into the causes, prevention, diagnosis and methods of treatment of
cancer.
Stephen Gallagher, Chief Executive Officer of Dotmatics, said: "We
began working with the ICR last year when it chose Dotmatics above
other providers for research tools in the Cancer Research UK Centre for
Cancer Therapeutics. We are immensely proud to be working with such a
prestigious organization and look forward to a close and fruitful
relationship with the ICR and its partners."
Professor Julian Blagg, Head of Medicinal Chemistry at the Centre
for Cancer Therapeutics said: "Dotmatics was chosen as our preferred
partner to meet our chemoinformatics needs; the cost effectiveness and
flexibility of the Dotmatics solution are particularly important to us.
The Dotmatics team have been very helpful in the implementation of the
platform across our centre and we look forward to working with
Dotmatics to develop and integrate new chemoinformatics tools to assist
our cancer drug discovery work."
is pleased to announce that it has licensed its enterprise query,
reporting, registration and data management tools to The Institute of
Cancer Research (ICR). The solution will primarily be used in the
Cancer Research UK Centre for Cancer Therapeutics to query, browse,
analyze and share chemical, biological and drug metabolism information
across research programs and project teams. Dotmatics and the ICR will
work closely together to identify and develop new tools to help
progress scientific efforts, especially those applicable to research
into the causes, prevention, diagnosis and methods of treatment of
cancer.
Stephen Gallagher, Chief Executive Officer of Dotmatics, said: "We
began working with the ICR last year when it chose Dotmatics above
other providers for research tools in the Cancer Research UK Centre for
Cancer Therapeutics. We are immensely proud to be working with such a
prestigious organization and look forward to a close and fruitful
relationship with the ICR and its partners."
Professor Julian Blagg, Head of Medicinal Chemistry at the Centre
for Cancer Therapeutics said: "Dotmatics was chosen as our preferred
partner to meet our chemoinformatics needs; the cost effectiveness and
flexibility of the Dotmatics solution are particularly important to us.
The Dotmatics team have been very helpful in the implementation of the
platform across our centre and we look forward to working with
Dotmatics to develop and integrate new chemoinformatics tools to assist
our cancer drug discovery work."
